Please Wait
Applying Filters...
menu
    • menu
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Rezafungin Acetate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 386,054Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mundipharma Completes Patient Enrollment In Phase 3 ReSPECT Trial
    Mundipharma Completes Patient Enrollment In Phase 3 ReSPECT Trial

    10 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-10/mundipharma-announces-patient-enrolment-completion-in-phase-iii-respect-clinical-trial-for-rezzayo

    PHARMIWEB
    10 Oct 2025
    Share Share
    Cormedix Completes Phase 3 ReSPECT Trial Enrollment For Rezzayo
    Cormedix Completes Phase 3 ReSPECT Trial Enrollment For Rezzayo

    29 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/29/3157711/0/en/CorMedix-Announces-Completion-of-Enrollment-in-Phase-III-ReSPECT-Clinical-Trial-for-REZZAYO.html

    GLOBENEWSWIRE
    29 Sep 2025
    Share Share
    Melinta Rezafungin Candida Data: Restore Outcomes, Breakpoints Published
    Melinta Rezafungin Candida Data: Restore Outcomes, Breakpoints Published

    23 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240523275178/en

    BUSINESSWIRE
    23 May 2024
    Share Share
    Cidara Divests Rezafungin to Mundipharma, Focuses on DFC Pipeline
    Cidara Divests Rezafungin to Mundipharma, Focuses on DFC Pipeline

    24 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/24/2869049/0/en/Cidara-Therapeutics-Announces-Divestiture-of-Rezafungin-to-Mundipharma-to-Focus-on-Advancing-the-Clinical-Development-of-Cloudbreak-DFC-Pipeline.html

    GLOBENEWSWIRE
    24 Apr 2024
    Share Share
    Mundipharma Acquires Rezafungin, Reinforces Infectious Disease Commitment
    Mundipharma Acquires Rezafungin, Reinforces Infectious Disease Commitment

    24 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240424542362/en

    BUSINESSWIRE
    24 Apr 2024
    Share Share
    Cidara Receives $11.14M Milestone Payment Following EU Approval of REZZAYO
    Cidara Receives $11.14M Milestone Payment Following EU Approval of REZZAYO

    12 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/12/2827490/0/en/Cidara-Therapeutics-Receives-11-14-Million-Milestone-Payment-Following-European-Approval-of-REZZAYO.html

    GLOBENEWSWIRE
    12 Feb 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.